ThirtyFiveBio

ThirtyFiveBio is a drug discovery company developing first-in-class small molecule inhibitors of GPR35, a genetically validated G protein-coupled receptor implicated in gastrointestinal disease.

The company's approach targets GPR35 antagonism to prevent epithelial cell damage and dysfunction in the gut wall, addressing underlying disease biology rather than inflammation directly.

Lead molecules are advancing through IND-enabling studies targeting ulcerative colitis and colorectal cancer.